Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release titled ‘Wockhardt’s Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.
The above information is a part of company’s filings submitted to BSE.
